MEDIFAST (MED) Stock Price, News & Analysis

Company Overview

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $14.24 to $14.90
• 50-Day Range: $12.09 to $14.65
• 52-Week Range: $11.57 to $22.66
• Volume: 193,541 shs
• Average Volume: 240,887 shs
• Market Capitalization: $160.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Hold

Medifast Stock Analysis - MarketRank™

Medifast scored higher than 69% of companies evaluated by MarketBeat, and ranked 74th out of 152 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Medifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Medifast has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for Medifast are expected to grow by 200.00% in the coming year, from $0.51 to $1.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medifast is -22.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medifast is -22.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medifast has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.65% of the float of Medifast has been sold short.

Short Interest Ratio / Days to Cover

Medifast has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Medifast has recently increased by 24.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medifast does not currently pay a dividend.

Dividend Growth

Medifast does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.0 / 5
• Environmental Score: -4.00

Percentage of Shares Shorted

15.65% of the float of Medifast has been sold short.

Short Interest Ratio / Days to Cover

Medifast has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Medifast has recently increased by 24.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for MED on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Medifast to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Medifast insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,003.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.90% of the stock of Medifast is held by insiders.

Percentage Held by Institutions

95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MED Stock Analysis - Frequently Asked Questions

How have MED shares performed this year?

Medifast's stock was trading at $17.62 at the beginning of the year. Since then, MED stock has decreased by 17.0% and is now trading at $14.62.
View the best growth stocks for 2025 here.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) posted its earnings results on Monday, April, 28th. The specialty retailer reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.04. The specialty retailer earned $115.73 million during the quarter, compared to the consensus estimate of $114.85 million. Medifast had a negative net margin of 1.29% and a positive trailing twelve-month return on equity of 6.63%.
Read the conference call transcript.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 4/28/2025
• Today: 7/02/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Consumer Staples
• Industry: FOOD - MISC/DIVERSIFIED
• Sub-Industry: Personal Products
• Current Symbol: NYSE:MED
• CIK: 910329
• Web: www.medifast1.com
• Phone: (410) 581-8042
• Fax: 410-581-8070
• Employees: 870
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.50
• High Stock Price Target: $16.50
• Low Stock Price Target: $16.50
• Potential Upside/Downside: +12.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 28.67
• P/E Growth: N/A
• Net Income: $2.09 million
• Net Margins: -1.29%
• Pretax Margin: -1.34%
• Return on Equity: 6.63%
• Return on Assets: 4.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.52
• Quick Ratio: 2.87

Sales & Book Value

• Annual Sales: $602.46 million
• Price / Sales: 0.27
• Cash Flow: $2.93 per share
• Price / Cash Flow: 4.99
• Book Value: $19.21 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 10,990,000
• Free Float: 10,672,000
• Market Cap: $160.67 million
• Optionable: Optionable
• Beta: 0.86